GlassScriptPhysician profile
Cindy Serra
NPI 1245644624
$3,879.97
in general payments reported to CMS, 2019-2025
16 companies · $807 in 2025
The $807 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $215 · 2021: $651 · 2022: $355 · 2023: $575 · 2024: $879 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $705.57 | 2022-2025 | Eysuvis, Rocklatan, Rhopressa |
| Novartis Pharmaceuticals Corporation | $703.16 | 2019-2023 | |
| Coopervision INC. | $686.99 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Allergan, INC. | $441.89 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $403.83 | 2022-2025 | Miebo, Xiidra |
| Biotissue Holdings INC. | $208.09 | 2021-2022 | |
| Dompe US, INC. | $144.24 | 2024-2025 | Oxervate |
| Shire North American Group INC | $140.75 | 2019 | |
| Abbvie INC. | $111.54 | 2023-2025 | Alphagan P, Lumigan, Vuity |
| Harrow Eye, LLC | $109.84 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $63.34 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $60.54 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.07 | 2020-2021 | |
| Horizon Therapeutics Plc | $25.41 | 2023 | Tepezza |
| Amgen INC. | $23.21 | 2024 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $18.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Serra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.